An example of EV-based therapy is the delivery of EV-miR-195 in CCA cells in vitro, which induces the suppression of cell growth via downregulating the expression of several pivotal proteins and growth factors such as cyclin-dependent kinases (CDK) 6, 1, and 4, which take part in cell cycle regulation, as well as VEGF. This evidence concerns the gene VEGFA and cholangiocarcinoma.